Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

ospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Product sales $2,858,573 $1,243,847 $10,456,700 $4,810,410

Costs and expenses:

Cost of product

sales 712,311 381,836 2,576,954 899,601

Research and

development 3,472,544 6,273,581 21,957,708 25,973,844

Selling, general

and

administrative 5,569,764 8,287,656 26,043,711 21,288,968

Total expenses 9,754,619 14,943,073 50,578,373 48,162,413

Loss from

operations (6,896,046) (13,699,226) (40,121,673) (43,352,003)

Interest income 61,587 147,764 543,442 895,685

Interest expense (55,352) (218,633) (584,276) (510,651)

Early extinguishment

of debt (224,048) - (224,048) -

Warrant expense (2,100,000) - (2,100,000) -

Other income - - 75,000 976,815

Loss including

noncontrolling

interest (9,213,859) (13,770,095) (42,411,555) (41,990,154)

Loss attributable

to noncontrolling

interest 162,189
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...of Financial Executives International , a 15,000-...emics, and audit committee members, has announced ...community influence. , ,The group offers an opport...about the ethics, highest standards, and best prac...t the business dynamics of the Madison area are di...
...ates Air Force contract to fund the development of...vide a Madison aerospace research and product deve...ld enable it to propel something much larger. , ,T...d $3.9 million to Orbital Technologies Corp. (Or...le, but it might issue additional delivery orders ...
...mn by Geoff Bastow , will dissect topics that i... community, including: entrepreneurship in IT, in...nd technology trends that are driving real busine...kee, Wis. - At the dawn of the dot-com era and t...March of 2000, Kenosha entrepreneur John Weiss was...
...classified contract from the defense sector, Plex...ered here, reported record revenues and earnings f...spite the closing of its manufacturing facility in...mpered, however, by forecasts of lower-than-expect...s stock price to fall by roughly one-third. , ,Rev...
Other Biology Technology:Orbitec will use $25 million Air Force contract to make small launch vehicle 2Leadership insights from co-founder of Yesmail 2Leadership insights from co-founder of Yesmail 3Leadership insights from co-founder of Yesmail 4Leadership insights from co-founder of Yesmail 5Defense contract helps Plexus gain record profits 2
(Date:7/24/2008)...s could talk, they might tell potential suitors, "...lltale come slither look. But worms send their val... chemical code researchers are now cracking, accor...he journal Nature . , Scientists from the Univ...nia Institute of Technology and the U.S. Departmen...
(Date:7/24/2008)... typhoon in Taiwan buries as much carbon in the oc... rains in that country all year long combined. ,...tudy published in a recent issue of the journal G...e the chemistry of stream water and sediments that...happening at full force -- will help scientists de...
(Date:7/23/2008)...tions willing to collectively spend about $1 billi...half a billion metric tons of carbon dioxide per y... , It would take about that much money to put an...he world, one of the top contributors to greenhous...ted, this type of program could have potential to ...
(Date:7/23/2008)... Institute of Standards and Technology (NIST) have... clumps of proteins in protein-based pharmaceutica...ditions under which scientists can be assured that...rmation of protein aggregates, a major concern bec...n biologic drug manufacturing. , Proteins, a mai...
Breaking Biology News(10 mins):Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3Study: Typhoons bury tons of carbon in the oceans 2Study: Typhoons bury tons of carbon in the oceans 3Study: Typhoons bury tons of carbon in the oceans 4Paying to save tropical forests could be a way to reduce global carbon emissions 2Paying to save tropical forests could be a way to reduce global carbon emissions 3Paying to save tropical forests could be a way to reduce global carbon emissions 4NIST trumps the clumps: Making biologic drugs safer 2BioNanomatrix Announces Appointment of Paul R Selvin to Its Scientific Advisory Board 4984 1BioNanomatrix Announces Appointment of Paul R Selvin to Its Scientific Advisory Board 4984 2BioNanomatrix Announces Appointment of Paul R Selvin to Its Scientific Advisory Board 4984 3Melanoma of the rectum 3A A rare entity 18032 1Determined a new method to establish the antioxidant capacity of extra virgin olive oil 18029 1Determined a new method to establish the antioxidant capacity of extra virgin olive oil 18029 2Ancient Nutcracker Man challenges ideas on evolution of human diet 3116 1Ancient Nutcracker Man challenges ideas on evolution of human diet 3116 2Ancient Nutcracker Man challenges ideas on evolution of human diet 3116 3
... made massive changes to the Earth,s landscape , ...andscape. But what was happening below the ice in ...s that it was a time of mass destruction as whole ...s scouring the sea floor. , In the past it has be...tinction by recolonising from nearby habitats that...
...n of airplanes from the Wright Brothers, first bip...he much earlier evolution of dinosaur flight, say ...ogist Sankar Chatterjee and retired aeronautical e...ur called Microraptor gui used a two-level, biplan...he early Cretaceous. Among the evidence for the ea...
...e of the tropics unfolds, scientists must explain ...to rapid human-population increase and environment...n the world increase, tropical forests are changin...ed, burned, logged, fragmented, and overhunted and...tered in insidious ways by global climatic and atm...
...suggests that restoring a gene often silenced in l...findings could lead to a new strategy for treating...own as WWOX, which is lost or silenced in a large ...east, ovary, prostate, bladder, esophagus and panc...tate University Comprehensive Cancer Center ? Arth...
Other Biology News:Seafloor creatures destroyed by ice action during ice ages 2Wright bros. upstaged! Dinos invented biplanes 2Wright bros. upstaged! Dinos invented biplanes 3Scientists must offer solutions for conserving tropical forests in a rapidly changing world 2Restoring silenced suppressor gene kills lung-cancer cells 2
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C
Request Info
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture.
Biology Products: